Evidence map›Paper›PMID 16107210›Full record

ArticleBMC genomics2005

Dual activation of pathways regulated by steroid receptors and peptide growth factors in primary prostate cancer revealed by Factor Analysis of microarray data.

Juan Jose Lozano, Marta Soler, Raquel Bermudo, David Abia, Pedro L Fernandez, Timothy M Thomson, Angel R Ortiz

Open access · goldAbstract read
In one paragraph

Article in BMC genomics, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. HER3 overexpression is a prognostic indicator of extrahepatic cholangiocarcinoma.Virchows Archiv : an international journal of pathology · 2012
    Article
  4. Article
  5. Article
  6. Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block.Immunology, endocrine & metabolic agents in medicinal chemistry · 2011
    Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Juan Jose LozanoBioinformatics Unit, Centro de Biología Molecular Severo Ochoa (CSIC-UAM), Universidad Autónoma de Madrid, Cantoblanco, 28049 Madrid, Spain. juanjo.lozano@crg.es
Marta Soler
Raquel Bermudo
David Abia
Pedro L Fernandez
Timothy M Thomson
Angel R Ortiz
Centre d’Investigació i Desenvolupament · ESCentro de Biología Molecular Severo Ochoa · ESConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESUniversidad Autónoma de Madrid · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe use an approach based on Factor Analysis to analyze datasets generated for transcriptional profiling. The method groups samples into biologically relevant categories, and enables the identification of genes and pathways most significantly associated to each phenotypic group, while allowing for the participation of a given gene in more than one cluster. Genes assigned to each cluster are used for the detection of pathways predominantly activated in that cluster by finding statistically significant associated GO terms. We tested the approach with a published dataset of microarray experiments in yeast. Upon validation with the yeast dataset, we applied the technique to a prostate cancer dataset.

resultsTwo major pathways are shown to be activated in organ-confined, non-metastatic prostate cancer: those regulated by the androgen receptor and by receptor tyrosine kinases. A number of gene markers (HER3, IQGAP2 and POR1) highlighted by the software and related to the later pathway have been validated experimentally a posteriori on independent samples.

conclusionUsing a new microarray analysis tool followed by a posteriori experimental validation of the results, we have confirmed several putative markers of malignancy associated with peptide growth factor signalling in prostate cancer and revealed others, most notably ERRB3 (HER3). Our study suggest that, in primary prostate cancer, HER3, together or not with HER4, rather than in receptor complexes involving HER2, could play an important role in the biology of these tumors. These results provide new evidence for the role of receptor tyrosine kinases in the establishment and progression of prostate cancer.

Indexed as

Gene Expression Regulation, NeoplasticBiomarkers, TumorCluster AnalysisErb-b2 Receptor Tyrosine KinasesErbB ReceptorsGenes, FungalGenome, FungalGenotypeGrowth SubstancesHumansImmunohistochemistryLasersMaleModels, GeneticModels, StatisticalMultigene FamilyBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesERBB4 protein, humanErbB ReceptorsGrowth SubstancesPeptidesReceptor, ErbB-3Receptor, ErbB-4Receptors, AndrogenReceptors, Steroid

Identifiers

PMID16107210
PMCPMC1239914
OpenAlexW1793153158

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.